Anatomy and Cell Biology

  • 제55권2호
  • /
  • Pages.179-189
  • /
  • 2022
  • /
  • 2093-3665(pISSN)
  • /
  • 2093-3673(eISSN)
대한해부학회 (Korean Association of Anatomists)
권호 표지
DOI QR코드

DOI QR Code

A study on the effect of JNJ-10397049 on proliferation and differentiation of neural precursor cells

  • Neda Karami (Division of Medical Biotechnology, Department of Laboratory Sciences, School of Paramedical Sciences, Shiraz University of Medical Sciences) ;
  • Hassan Azari (Neural Stem Cell Laboratory, Department of Neurosurgery, McKnight Brain Institute, University of Florida) ;
  • Moosa Rahimi (Laboratory of Basic Sciences, Mohammad Rasul Allah Research Tower, Shiraz University of Medical Sciences) ;
  • Hadi Aligholi (Department of Neuroscience, School of Advanced Medical Sciences and Technology, Shiraz University of Medical Sciences) ;
  • Tahereh Kalantari (Division of Medical Biotechnology, Department of Laboratory Sciences, School of Paramedical Sciences, Shiraz University of Medical Sciences)
  • 투고 : 2021.10.03
  • 심사 : 2021.12.27
  • 발행 : 2022.06.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

The orexin 2 receptor plays a central role in maintaining sleep and wakefulness. Recently, it has been shown that sleep and wakefulness orchestrate the proliferation and differentiation of oligodendrocytes. Here, we explored the role of a selective orexin 2 receptor antagonist (JNJ-10397049) in proliferation and differentiation of neural progenitor cells (NPCs). We evaluated the proliferation potential of NPCs after exposure to different concentrations of JNJ-10397049 by using 3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyl tetrazolium bromide and neurosphere assays. Moreover, the expression of differentiation markers was assessed by immunocytochemistry and real-time polymerase chain reaction. JNJ-10397049 significantly increased the proliferation of NPCs at lower concentrations. In addition, orexin 2 receptor antagonist facilitated progression of differentiation of NPCs towards oligodendroglial lineage by considerable expression of Olig2 and 2',3'-cyclicnucleotide 3'-phosphodiesterase as well as decreased expression of nestin marker. The results open a new avenue for future investigations in which the production of more oligodendrocytes from NPCs is needed.

키워드

과제정보

This work was financially supported by a grant number 14482 from Shiraz University of Medical Sciences, Shiraz, Iran. We are grateful to Zahra Zeraatpisheh and Marjan Ghorbanpour for their technical help and support. We had collaboration with Department of Neuroscience, School of Advanced Medical Sciences and Technology for performing this research.

참고문헌

  1. Gage FH. Mammalian neural stem cells. Science 2000;287:1433-8. https://doi.org/10.1126/science.287.5457.1433
  2. Ming GL, Song H. Adult neurogenesis in the mammalian brain: significant answers and significant questions. Neuron 2011;70:687-702.
  3. Takano M, Kawabata S, Shibata S, Yasuda A, Nori S, Tsuji O, Nagoshi N, Iwanami A, Ebise H, Horiuchi K, Okano H, Nakamura M. Enhanced functional recovery from spinal cord injury in aged mice after stem cell transplantation through HGF induction. Stem Cell Reports 2017;8:509-18. https://doi.org/10.1016/j.stemcr.2017.01.013
  4. Desai RA, Davies AL, Tachrount M, Kasti M, Laulund F, Golay X, Smith KJ. Cause and prevention of demyelination in a model multiple sclerosis lesion. Ann Neurol 2016;79:591-604. https://doi.org/10.1002/ana.24607
  5. Haider L, Zrzavy T, Hametner S, Hoftberger R, Bagnato F, Grabner G, Trattnig S, Pfeifenbring S, Bruck W, Lassmann H. The topograpy of demyelination and neurodegeneration in the multiple sclerosis brain. Brain 2016;139(Pt 3):807-15. https://doi.org/10.1093/brain/awv398
  6. Cohen-Adad J, El Mendili MM, Lehericy S, Pradat PF, Blancho S, Rossignol S, Benali H. Demyelination and degeneration in the injured human spinal cord detected with diffusion and magnetization transfer MRI. Neuroimage 2011;55:1024-33. https://doi.org/10.1016/j.neuroimage.2010.11.089
  7. Bouhrara M, Reiter DA, Bergeron CM, Zukley LM, Ferrucci L, Resnick SM, Spencer RG. Evidence of demyelination in mild cognitive impairment and dementia using a direct and specific magnetic resonance imaging measure of myelin content. Alzheimers Dement 2018;14:998-1004. https://doi.org/10.1016/j.jalz.2018.03.007
  8. Mitew S, Kirkcaldie MT, Halliday GM, Shepherd CE, Vickers JC, Dickson TC. Focal demyelination in Alzheimer's disease and transgenic mouse models. Acta Neuropathol 2010;119:567-77. https://doi.org/10.1007/s00401-010-0657-2
  9. Franklin RJ, Ffrench-Constant C. Remyelination in the CNS: from biology to therapy. Nat Rev Neurosci 2008;9:839-55. https://doi.org/10.1038/nrn2480
  10. Yue T, Xian K, Hurlock E, Xin M, Kernie SG, Parada LF, Lu QR. A critical role for dorsal progenitors in cortical myelination. J Neurosci 2006;26:1275-80. https://doi.org/10.1523/JNEUROSCI.4717-05.2006
  11. Lubetzki C, Zalc B, Williams A, Stadelmann C, Stankoff B. Remyelination in multiple sclerosis: from basic science to clinical translation. Lancet Neurol 2020;19:678-88. https://doi.org/10.1016/S1474-4422(20)30140-X
  12. Melchor GS, Khan T, Reger JF, Huang JK. Remyelination pharmacotherapy investigations highlight diverse mechanisms underlying multiple sclerosis progression. ACS Pharmacol Transl Sci 2019;2:372-86. https://doi.org/10.1021/acsptsci.9b00068
  13. Chen Y, Zhen W, Guo T, Zhao Y, Liu A, Rubio JP, Krull D, Richardson JC, Lu H, Wang R. Histamine receptor 3 negatively regulates oligodendrocyte differentiation and remyelination. PLoS One 2017;12:e0189380.
  14. Fan LW, Bhatt A, Tien LT, Zheng B, Simpson KL, Lin RC, Cai Z, Kumar P, Pang Y. Exposure to serotonin adversely affects oligodendrocyte development and myelination in vitro. J Neurochem 2015;133:532-43. https://doi.org/10.1111/jnc.12988
  15. Ghareghani M, Sadeghi H, Zibara K, Danaei N, Azari H, Ghanbari A. Melatonin increases oligodendrocyte differentiation in cultured neural stem cells. Cell Mol Neurobiol 2017;37:1319-24. https://doi.org/10.1007/s10571-016-0450-4
  16. Olivier P, Fontaine RH, Loron G, Van Steenwinckel J, Biran V, Massonneau V, Kaindl A, Dalous J, Charriaut-Marlangue C, Aigrot MS, Pansiot J, Verney C, Gressens P, Baud O. Melatonin promotes oligodendroglial maturation of injured white matter in neonatal rats. PLoS One 2009;4:e7128.
  17. Sotthibundhu A, Phansuwan-Pujito P, Govitrapong P. Melatonin increases proliferation of cultured neural stem cells obtained from adult mouse subventricular zone. J Pineal Res 2010;49:291-300. https://doi.org/10.1111/j.1600-079X.2010.00794.x
  18. Sakurai T, Mieda M. Connectomics of orexin-producing neurons: interface of systems of emotion, energy homeostasis and arousal. Trends Pharmacol Sci 2011;32:451-62. https://doi.org/10.1016/j.tips.2011.03.007
  19. Yin J, Babaoglu K, Brautigam CA, Clark L, Shao Z, Scheuermann TH, Harrell CM, Gotter AL, Roecker AJ, Winrow CJ, Renger JJ, Coleman PJ, Rosenbaum DM. Structure and ligand-binding mechanism of the human OX1 and OX2 orexin receptors. Nat Struct Mol Biol 2016;23:293-9. https://doi.org/10.1038/nsmb.3183
  20. Ng MC. Orexin and epilepsy: potential role of REM sleep. Sleep 2017;40:zsw061.
  21. Soya S, Takahashi TM, McHugh TJ, Maejima T, Herlitze S, Abe M, Sakimura K, Sakurai T. Orexin modulates behavioral fear expression through the locus coeruleus. Nat Commun 2017;8:1606.
  22. Liblau RS, Vassalli A, Seifinejad A, Tafti M. Hypocretin (orexin) biology and the pathophysiology of narcolepsy with cataplexy. Lancet Neurol 2015;14:318-28. https://doi.org/10.1016/S1474-4422(14)70218-2
  23. Liguori C. Orexin and Alzheimer's disease. Curr Top Behav Neurosci 2017;33:305-22.
  24. Liu RJ, van den Pol AN, Aghajanian GK. Hypocretins (orexins) regulate serotonin neurons in the dorsal raphe nucleus by excitatory direct and inhibitory indirect actions. J Neurosci 2002;22:9453-64.
  25. Lyons DJ, Hellysaz A, Ammari R, Broberger C. Hypocretin/orexin peptides excite rat neuroendocrine dopamine neurons through orexin 2 receptor-mediated activation of a mixed cation current. Sci Rep 2017;7:41535.
  26. Tao R, Ma Z, McKenna JT, Thakkar MM, Winston S, Strecker RE, McCarley RW. Differential effect of orexins (hypocretins) on serotonin release in the dorsal and median raphe nuclei of freely behaving rats. Neuroscience 2006;141:1101-5. https://doi.org/10.1016/j.neuroscience.2006.05.027
  27. Yamada N, Katsuura G, Tatsuno I, Asaki T, Kawahara S, Ebihara K, Saito Y, Nakao K. Orexin decreases mRNA expressions of NMDA and AMPA receptor subunits in rat primary neuron cultures. Peptides 2008;29:1582-7. https://doi.org/10.1016/j.peptides.2008.05.002
  28. Yamanaka A, Tsujino N, Funahashi H, Honda K, Guan JL, Wang QP, Tominaga M, Goto K, Shioda S, Sakurai T. Orexins activate histaminergic neurons via the orexin 2 receptor. Biochem Biophys Res Commun 2002;290:1237-45. https://doi.org/10.1006/bbrc.2001.6318
  29. Yin J, Mobarec JC, Kolb P, Rosenbaum DM. Crystal structure of the human OX2 orexin receptor bound to the insomnia drug suvorexant. Nature 2015;519:247-50. https://doi.org/10.1038/nature14035
  30. Azari H, Sharififar S, Rahman M, Ansari S, Reynolds BA. Establishing embryonic mouse neural stem cell culture using the neurosphere assay. J Vis Exp 2011;(47):2457.
  31. Lassmann H, van Horssen J. The molecular basis of neurodegeneration in multiple sclerosis. FEBS Lett 2011;585:3715-23. https://doi.org/10.1016/j.febslet.2011.08.004
  32. Geurts JJ, Bo L, Roosendaal SD, Hazes T, Daniels R, Barkhof F, Witter MP, Huitinga I, van der Valk P. Extensive hippocampal demyelination in multiple sclerosis. J Neuropathol Exp Neurol 2007;66:819-27. https://doi.org/10.1097/nen.0b013e3181461f54
  33. Kim LJ, Martinez D, Fiori CZ, Baronio D, Kretzmann NA, Barros HM. Hypomyelination, memory impairment, and blood-brain barrier permeability in a model of sleep apnea. Brain Res 2015;1597:28-36.
  34. Pillai JA, Leverenz JB. Sleep and neurodegeneration: a critical appraisal. Chest 2017;151:1375-86. https://doi.org/10.1016/j.chest.2017.01.002
  35. Mothe AJ, Tam RY, Zahir T, Tator CH, Shoichet MS. Repair of the injured spinal cord by transplantation of neural stem cells in a hyaluronan-based hydrogel. Biomaterials 2013;34:3775-83. https://doi.org/10.1016/j.biomaterials.2013.02.002
  36. Wolswijk G. Chronic stage multiple sclerosis lesions contain a relatively quiescent population of oligodendrocyte precursor cells. J Neurosci 1998;18:601-9. https://doi.org/10.1523/JNEUROSCI.18-02-00601.1998
  37. Yousefifard M, Rahimi-Movaghar V, Nasirinezhad F, Baikpour M, Safari S, Saadat S, Moghadas Jafari A, Asady H, Razavi Tousi SM, Hosseini M. Neural stem/progenitor cell transplantation for spinal cord injury treatment; a systematic review and meta-analysis. Neuroscience 2016;322:377-97. https://doi.org/10.1016/j.neuroscience.2016.02.034
  38. Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM, Tanaka H, Williams SC, Richardson JA, Kozlowski GP, Wilson S, Arch JR, Buckingham RE, Haynes AC, Carr SA, Annan RS, McNulty DE, Liu WS, Terrett JA, Elshourbagy NA, Bergsma DJ, Yanagisawa M. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 1998;92:573-85. https://doi.org/10.1016/S0092-8674(00)80949-6
  39. Recourt K, de Boer P, Zuiker R, Luthringer R, Kent J, van der Ark P, Van Hove I, van Gerven J, Jacobs G, van Nueten L, Drevets W. The selective orexin-2 antagonist seltorexant (JNJ-42847922/MIN-202) shows antidepressant and sleep-promoting effects in patients with major depressive disorder. Transl Psychiatry 2019;9:216. Erratum in: Transl Psychiatry 2019;9:240.
  40. Zammit G, Dauvilliers Y, Pain S, Sebok Kinter D, Mansour Y, Kunz D. Daridorexant, a new dual orexin receptor antagonist, in elderly subjects with insomnia disorder. Neurology 2020;94:e2222-32.
  41. Elam HB, Perez SM, Donegan JJ, Lodge DJ. Orexin receptor antagonists reverse aberrant dopamine neuron activity and related behaviors in a rodent model of stress-induced psychosis. Transl Psychiatry 2021;11:114.
  42. Brooks S, Jacobs GE, de Boer P, Kent JM, Van Nueten L, van Amerongen G, Zuiker R, Kezic I, Luthringer R, van der Ark P, van Gerven JM, Drevets W. The selective orexin-2 receptor antagonist seltorexant improves sleep: an exploratory double-blind, placebo controlled, crossover study in antidepressant-treated major depressive disorder patients with persistent insomnia. J Psychopharmacol 2019;33:202-9. https://doi.org/10.1177/0269881118822258
  43. Dubey AK, Handu SS, Mediratta PK. Suvorexant: the first orexin receptor antagonist to treat insomnia. J Pharmacol Pharmacother 2015;6:118-21.
  44. Kishi T, Matsunaga S, Iwata N. Suvorexant for primary insomnia: a systematic review and meta-analysis of randomized placebo-controlled trials. PLoS One 2015;10:e0136910.
  45. Scammell TE, Winrow CJ. Orexin receptors: pharmacology and therapeutic opportunities. Annu Rev Pharmacol Toxicol 2011;51:243-66. https://doi.org/10.1146/annurev-pharmtox-010510-100528
  46. Roth T, Black J, Cluydts R, Charef P, Cavallaro M, Kramer F, Zammit G, Walsh J. Dual orexin receptor antagonist, almorexant, in elderly patients with primary insomnia: a randomized, controlled study. Sleep 2017;40:zsw034.
  47. Braley TJ, Kratz AL, Kaplish N, Chervin RD. Sleep and cognitive function in multiple sclerosis. Sleep 2016;39:1525-33. https://doi.org/10.5665/sleep.6012
  48. Bellesi M, Pfister-Genskow M, Maret S, Keles S, Tononi G, Cirelli C. Effects of sleep and wake on oligodendrocytes and their precursors. J Neurosci 2013;33:14288-300. https://doi.org/10.1523/JNEUROSCI.5102-12.2013
  49. Andretic R, Franken P, Tafti M. Genetics of sleep. Annu Rev Genet 2008;42:361-88. https://doi.org/10.1146/annurev.genet.42.110807.091541
  50. Bellesi M, Haswell JD, de Vivo L, Marshall W, Roseboom PH, Tononi G, Cirelli C. Myelin modifications after chronic sleep loss in adolescent mice. Sleep 2018;41:zsy034.
  51. Becquet L, Abad C, Leclercq M, Miel C, Jean L, Riou G, Couvineau A, Boyer O, Tan YV. Systemic administration of orexin A ameliorates established experimental autoimmune encephalomyelitis by diminishing neuroinflammation. J Neuroinflammation 2019;16:64.
  52. Fatemi I, Shamsizadeh A, Ayoobi F, Taghipour Z, Sanati MH, Roohbakhsh A, Motevalian M. Role of orexin-A in experimental autoimmune encephalomyelitis. J Neuroimmunol 2016;291:101-9. https://doi.org/10.1016/j.jneuroim.2016.01.001
  53. Gencer M, Akbayir E, Sen M, Arsoy E, Yilmaz V, Bulut N, Tuzun E, Turkoglu R. Serum orexin-A levels are associated with disease progression and motor impairment in multiple sclerosis. Neurol Sci 2019;40:1067-70. https://doi.org/10.1007/s10072-019-3708-z
  54. Long KLP, Breton JM, Barraza MK, Perloff OS, Kaufer D. Hormonal regulation of oligodendrogenesis I: effects across the lifespan. Biomolecules 2021;11:283.
  55. Armada-Moreira A, Ribeiro FF, Sebastiao AM, Xapelli S. Neuroinflammatory modulators of oligodendrogenesis. Neuroimmunol Neuroinflammation 2015;2:263-73. https://doi.org/10.4103/2347-8659.167311
  56. Li H, He Y, Richardson WD, Casaccia P. Two-tier transcriptional control of oligodendrocyte differentiation. Curr Opin Neurobiol 2009;19:479-85.
  57. Copray S, Balasubramaniyan V, Levenga J, de Bruijn J, Liem R, Boddeke E. Olig2 overexpression induces the in vitro differentiation of neural stem cells into mature oligodendrocytes. Stem Cells 2006;24:1001-10.
  58. Mei F, Wang H, Liu S, Niu J, Wang L, He Y, Etxeberria A, Chan JR, Xiao L. Stage-specific deletion of Olig2 conveys opposing functions on differentiation and maturation of oligodendrocytes. J Neurosci 2013;33:8454-62. https://doi.org/10.1523/JNEUROSCI.2453-12.2013
  59. Raasakka A, Myllykoski M, Laulumaa S, Lehtimaki M, Hartlein M, Moulin M, Kursula I, Kursula P. Determinants of ligand binding and catalytic activity in the myelin enzyme 2',3'-cyclic nucleotide 3'-phosphodiesterase. Sci Rep 2015;5:16520.
  60. Rosener M, Muraro PA, Riethmuller A, Kalbus M, Sappler G, Thompson RJ, Lichtenfels R, Sommer N, McFarland HF, Martin R. 2',3'-cyclic nucleotide 3'-phosphodiesterase: a novel candidate autoantigen in demyelinating diseases. J Neuroimmunol 1997;75:28-34. https://doi.org/10.1016/S0165-5728(96)00230-5
  61. Scherer SS, Braun PE, Grinspan J, Collarini E, Wang DY, Kamholz J. Differential regulation of the 2',3'-cyclic nucleotide 3'-phosphodiesterase gene during oligodendrocyte development. Neuron 1994;12:1363-75. https://doi.org/10.1016/0896-6273(94)90451-0
  62. Raasakka A, Kursula P. The myelin membrane-associated enzyme 2',3'-cyclic nucleotide 3'-phosphodiesterase: on a highway to structure and function. Neurosci Bull 2014;30:956-66. https://doi.org/10.1007/s12264-013-1437-5